Lymphoma Treatment Denied by Insurance: How to Appeal

Lymphoma — encompassing Hodgkin lymphoma, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, and dozens of other subtypes — is treated with some of the most expensive and logistically complex interventions in oncology. CAR-T cell therapies, autologous stem cell transplants (ASCT), rituximab-based chemoimmunotherapy regimens, and high-frequency PET/CT surveillance are all regularly denied by insurers. These denials disrupt care at critical moments. They are also frequently overturned on appeal.

Common Lymphoma Denial Scenarios

CAR-T Cell Therapy (Yescarta, Kymriah, Breyanzi)

Axicabtagene ciloleucel (Yescarta), tisagenlecleucel (Kymriah), and lisocabtagene maraleucel (Breyanzi) are FDA-approved for relapsed or refractory large B-cell lymphoma after two or more prior lines of therapy. Yescarta and Breyanzi also carry second-line approvals for eligible patients. Insurance denials for CAR-T in lymphoma typically involve:

• "Center of excellence" requirements — insurers requiring treatment at a FACT-accredited facility, which is clinically appropriate, but then approving only centers far from the patient
• Bridging therapy denials — refusing to cover the chemotherapy administered while CAR-T cells are being manufactured
• Administrative delays that extend the manufacturing wait and allow disease progression
• Denying second-line CAR-T, citing the prior two-line requirement incorrectly for patients who qualify under newer approvals

Autologous Stem Cell Transplant (ASCT)

ASCT is standard of care for relapsed/refractory Hodgkin lymphoma and DLBCL in appropriate candidates. Insurers routinely require preauthorization and may deny based on:

• The patient's age or performance status, using overly conservative thresholds
• "Investigational" language for ASCT in less common lymphoma subtypes despite strong evidence
• The donor search and workup process (for allogeneic transplant) as separate denied claims

Rituximab and Biosimilars

Rituximab is the backbone of R-CHOP and R-CVP regimens for B-cell lymphomas. Biosimilars (rituximab-pvvr, rituximab-arrx) are increasingly preferred by insurers for cost reasons. Patients and oncologists may prefer the reference product. Insurers may switch patients mid-treatment to a biosimilar without clinical justification. If your oncologist has documented reasons to maintain the original formulation, this can be appealed.

PET/CT Scan Frequency

Positron emission tomography (PET/CT) is the standard imaging modality for lymphoma staging and treatment response assessment. The Lugano Classification recommends PET/CT at diagnosis, interim (after 2-4 cycles), and end of treatment. Insurers frequently deny interim PET scans or surveillance imaging after treatment, citing "excessive frequency" even when NCCN guidelines and ASCO recommendations support the imaging schedule.

The Challenge of CAR-T Authorization

CAR-T cell therapy requires a particularly careful approach to insurance authorization because:

1. Manufacturing timelines are fixed: Once leukapheresis (cell collection) begins, the process cannot wait indefinitely. Delays caused by insurance denials can lead to disease progression that disqualifies a patient from receiving the therapy they were already approved to undergo.

2. Bridging therapy is medically essential: Many patients need chemotherapy during the 3-4 week manufacturing period to control rapidly progressing disease. Denying bridging therapy while approving CAR-T creates an impossible clinical situation.

3. Center restrictions: If an insurer's only in-network CAR-T center is hundreds of miles away, out-of-network necessity exceptions should apply.

Your Legal Rights

ERISA and ACA protections: Coverage of CAR-T cell therapy is required when it is FDA-approved for the patient's diagnosis and treatment line. "Not medically necessary" denials for FDA-approved CAR-T in eligible patients are aggressively challenged.

External Independent Review: Complete Guide" class="auto-link">External review rights: Independent external review of CAR-T denials should be requested immediately if internal appeal fails. External reviewers overturn a significant portion of oncology denials.

Urgency and expedited review: When a treatment denial creates an urgent clinical situation — as is common in lymphoma, where disease can progress rapidly — you have the right to request an expedited appeal decision within 72 hours.

How to Build Your Appeal

1. Diagnosis documentation: Pathology report with lymphoma subtype, immunohistochemistry, cytogenetics, and staging workup
2. Prior treatment history: Documentation that the patient has received the required number of prior lines (usually 2+) for CAR-T eligibility
3. PET/CT imaging: Showing active, refractory disease
4. NCCN Lymphoma Guidelines: Specific to the lymphoma subtype (DLBCL, Hodgkin, follicular, MCL)
5. Letter of medical necessity: From the treating hematologic oncologist, ideally at an NCI-designated cancer center
6. FDA labeling for the specific CAR-T product and indication

For CAR-T appeals, emphasize the time-sensitive nature of the manufacturing process and the clinical consequences of delay.

Fight Back With ClaimBack

ClaimBack helps lymphoma patients and their families navigate insurance denials for complex, high-stakes treatments including CAR-T cell therapy and stem cell transplant. We provide the tools to build a compelling, clinically grounded appeal.

Start your appeal at ClaimBack

Lymphoma treatment denials are serious, but they are not irreversible. With the right appeal, patients regularly access the treatments their oncologists have prescribed.

Related Reading

• How to Write an Insurance Appeal Letter
• Internal vs. External Insurance Appeals
• Common Reasons Insurance Claims Are Denied